Stock Market & Financial Investment News

News For LLY;SNY From The Last 14 Days Check below for free stories on LLY;SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 07:44 EDT SNY Sachs Associates to host a forum Subscribe for More Information 07:24 EDT LLY Global Health Care to host a conference Subscribe for More Information May 20, 2013 17:26 EDT SNY Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement' Subscribe for More Information 11:27 EDT SNY Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva Subscribe for More Information May 17, 2013 08:03 EDT SNY Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information 05:18 EDT SNY Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information May 16, 2013 08:55 EDT LLY BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information May 15, 2013 15:16 EDT SNY Sanofi systemic sclerosis treatment designated for orphan drug status Subscribe for More Information 05:39 EDT SNY Sanofi, Regeneron announce patient enrollment in two Phase 3 trials Subscribe for More Information May 14, 2013 09:09 EDT LLY Eli Lilly announces CEO John Lechleiter recovering from surgery Subscribe for More Information 07:24 EDT LLY EBD Group to host a conference BioTrinity 2013 is being held in Newbury, England on May 14-16. May 13, 2013 09:44 EDT SNY Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:30 EDT SNY TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. May 10, 2013 11:48 EDT SNY, LLY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 08:02 EDT LLY Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. May 9, 2013 11:01 EDT LLY Sears Holdings names Jeff Balagna Chief Information Officer Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.